A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer

Kevin D. Courtney, Judith B. Manola, Aymen A. Elfiky, Robert Ross, William K. Oh, Jeffrey T. Yap, Annick D. Van Den Abbeele, Christopher Ryan, Tomasz (Tom) Beer, Massimo Loda, Carmen Priolo, Philip Kantoff, Mary Ellen Taplin

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Background The PTEN tumor suppressor is frequently lost in CRPC, with activation of Akt-mTOR signaling, driving growth. We conducted a phase I trial of the mTOR inhibitor, everolimus, and docetaxel in CRPC. Patients and Methods Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Patients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG-PET/computed tomography scan. Patient cohorts were subsequently treated at 3 dose levels of everolimus with docetaxel: 5 mg to 60 mg/m2, 10 mg to 60 mg/m2, and 10 mg to 70 mg/m2. The primary end point was the safety and tolerability of combination therapy. Results Accrual was 4 patients at level 1, 3 patients at level 2, and 8 patients at level 3. Common toxicities were hematologic and fatigue. Serum concentrations of everolimus when administered with docetaxel were 1.5 to 14.8 ng/mL in patients receiving 5 mg everolimus and 4.5 to 55.4 ng/mL in patients receiving 10 mg everolimus. Four patients had partial metabolic response (PMR) using FDG-PET, 12 had stable metabolic disease, and 2 had progressive metabolic disease after a 2-week treatment with everolimus alone. Five of 12 evaluable patients experienced a prostate-specific antigen (PSA) reduction ≥ 50% during treatment with everolimus together with docetaxel. All 4 patients with a PMR according to PET imaging experienced a PSA reduction in response to everolimus with docetaxel, and 3 of 4 had PSA declines ≥ 50%. Conclusion Everolimus 10 mg daily and docetaxel 60 mg/m2 was safe in CRPC patients and these were the recommended doses in combination. FDG-PET response might serve as a biomarker for target inhibition by mTOR inhibitors.

    Original languageEnglish (US)
    Pages (from-to)113-123
    Number of pages11
    JournalClinical Genitourinary Cancer
    Volume13
    Issue number2
    DOIs
    StatePublished - Apr 1 2015

    Fingerprint

    docetaxel
    Castration
    Prostatic Neoplasms
    Prostate-Specific Antigen
    Metabolic Diseases
    Everolimus

    Keywords

    • mTOR
    • PI3K
    • Positron emission tomography
    • Prostatic adenocarcinoma
    • PTEN

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Courtney, K. D., Manola, J. B., Elfiky, A. A., Ross, R., Oh, W. K., Yap, J. T., ... Taplin, M. E. (2015). A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clinical Genitourinary Cancer, 13(2), 113-123. https://doi.org/10.1016/j.clgc.2014.08.007

    A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer. / Courtney, Kevin D.; Manola, Judith B.; Elfiky, Aymen A.; Ross, Robert; Oh, William K.; Yap, Jeffrey T.; Van Den Abbeele, Annick D.; Ryan, Christopher; Beer, Tomasz (Tom); Loda, Massimo; Priolo, Carmen; Kantoff, Philip; Taplin, Mary Ellen.

    In: Clinical Genitourinary Cancer, Vol. 13, No. 2, 01.04.2015, p. 113-123.

    Research output: Contribution to journalArticle

    Courtney, KD, Manola, JB, Elfiky, AA, Ross, R, Oh, WK, Yap, JT, Van Den Abbeele, AD, Ryan, C, Beer, TT, Loda, M, Priolo, C, Kantoff, P & Taplin, ME 2015, 'A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer', Clinical Genitourinary Cancer, vol. 13, no. 2, pp. 113-123. https://doi.org/10.1016/j.clgc.2014.08.007
    Courtney, Kevin D. ; Manola, Judith B. ; Elfiky, Aymen A. ; Ross, Robert ; Oh, William K. ; Yap, Jeffrey T. ; Van Den Abbeele, Annick D. ; Ryan, Christopher ; Beer, Tomasz (Tom) ; Loda, Massimo ; Priolo, Carmen ; Kantoff, Philip ; Taplin, Mary Ellen. / A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer. In: Clinical Genitourinary Cancer. 2015 ; Vol. 13, No. 2. pp. 113-123.
    @article{470100fbb9d74485b24973771e3925e5,
    title = "A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer",
    abstract = "Background The PTEN tumor suppressor is frequently lost in CRPC, with activation of Akt-mTOR signaling, driving growth. We conducted a phase I trial of the mTOR inhibitor, everolimus, and docetaxel in CRPC. Patients and Methods Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Patients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG-PET/computed tomography scan. Patient cohorts were subsequently treated at 3 dose levels of everolimus with docetaxel: 5 mg to 60 mg/m2, 10 mg to 60 mg/m2, and 10 mg to 70 mg/m2. The primary end point was the safety and tolerability of combination therapy. Results Accrual was 4 patients at level 1, 3 patients at level 2, and 8 patients at level 3. Common toxicities were hematologic and fatigue. Serum concentrations of everolimus when administered with docetaxel were 1.5 to 14.8 ng/mL in patients receiving 5 mg everolimus and 4.5 to 55.4 ng/mL in patients receiving 10 mg everolimus. Four patients had partial metabolic response (PMR) using FDG-PET, 12 had stable metabolic disease, and 2 had progressive metabolic disease after a 2-week treatment with everolimus alone. Five of 12 evaluable patients experienced a prostate-specific antigen (PSA) reduction ≥ 50{\%} during treatment with everolimus together with docetaxel. All 4 patients with a PMR according to PET imaging experienced a PSA reduction in response to everolimus with docetaxel, and 3 of 4 had PSA declines ≥ 50{\%}. Conclusion Everolimus 10 mg daily and docetaxel 60 mg/m2 was safe in CRPC patients and these were the recommended doses in combination. FDG-PET response might serve as a biomarker for target inhibition by mTOR inhibitors.",
    keywords = "mTOR, PI3K, Positron emission tomography, Prostatic adenocarcinoma, PTEN",
    author = "Courtney, {Kevin D.} and Manola, {Judith B.} and Elfiky, {Aymen A.} and Robert Ross and Oh, {William K.} and Yap, {Jeffrey T.} and {Van Den Abbeele}, {Annick D.} and Christopher Ryan and Beer, {Tomasz (Tom)} and Massimo Loda and Carmen Priolo and Philip Kantoff and Taplin, {Mary Ellen}",
    year = "2015",
    month = "4",
    day = "1",
    doi = "10.1016/j.clgc.2014.08.007",
    language = "English (US)",
    volume = "13",
    pages = "113--123",
    journal = "Clinical Genitourinary Cancer",
    issn = "1558-7673",
    publisher = "Elsevier",
    number = "2",

    }

    TY - JOUR

    T1 - A phase i study of everolimus and docetaxel in patients with castration-resistant prostate cancer

    AU - Courtney, Kevin D.

    AU - Manola, Judith B.

    AU - Elfiky, Aymen A.

    AU - Ross, Robert

    AU - Oh, William K.

    AU - Yap, Jeffrey T.

    AU - Van Den Abbeele, Annick D.

    AU - Ryan, Christopher

    AU - Beer, Tomasz (Tom)

    AU - Loda, Massimo

    AU - Priolo, Carmen

    AU - Kantoff, Philip

    AU - Taplin, Mary Ellen

    PY - 2015/4/1

    Y1 - 2015/4/1

    N2 - Background The PTEN tumor suppressor is frequently lost in CRPC, with activation of Akt-mTOR signaling, driving growth. We conducted a phase I trial of the mTOR inhibitor, everolimus, and docetaxel in CRPC. Patients and Methods Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Patients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG-PET/computed tomography scan. Patient cohorts were subsequently treated at 3 dose levels of everolimus with docetaxel: 5 mg to 60 mg/m2, 10 mg to 60 mg/m2, and 10 mg to 70 mg/m2. The primary end point was the safety and tolerability of combination therapy. Results Accrual was 4 patients at level 1, 3 patients at level 2, and 8 patients at level 3. Common toxicities were hematologic and fatigue. Serum concentrations of everolimus when administered with docetaxel were 1.5 to 14.8 ng/mL in patients receiving 5 mg everolimus and 4.5 to 55.4 ng/mL in patients receiving 10 mg everolimus. Four patients had partial metabolic response (PMR) using FDG-PET, 12 had stable metabolic disease, and 2 had progressive metabolic disease after a 2-week treatment with everolimus alone. Five of 12 evaluable patients experienced a prostate-specific antigen (PSA) reduction ≥ 50% during treatment with everolimus together with docetaxel. All 4 patients with a PMR according to PET imaging experienced a PSA reduction in response to everolimus with docetaxel, and 3 of 4 had PSA declines ≥ 50%. Conclusion Everolimus 10 mg daily and docetaxel 60 mg/m2 was safe in CRPC patients and these were the recommended doses in combination. FDG-PET response might serve as a biomarker for target inhibition by mTOR inhibitors.

    AB - Background The PTEN tumor suppressor is frequently lost in CRPC, with activation of Akt-mTOR signaling, driving growth. We conducted a phase I trial of the mTOR inhibitor, everolimus, and docetaxel in CRPC. Patients and Methods Eligible patients had progressive, metastatic, chemotherapy-naive CRPC. Patients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG-PET/computed tomography scan. Patient cohorts were subsequently treated at 3 dose levels of everolimus with docetaxel: 5 mg to 60 mg/m2, 10 mg to 60 mg/m2, and 10 mg to 70 mg/m2. The primary end point was the safety and tolerability of combination therapy. Results Accrual was 4 patients at level 1, 3 patients at level 2, and 8 patients at level 3. Common toxicities were hematologic and fatigue. Serum concentrations of everolimus when administered with docetaxel were 1.5 to 14.8 ng/mL in patients receiving 5 mg everolimus and 4.5 to 55.4 ng/mL in patients receiving 10 mg everolimus. Four patients had partial metabolic response (PMR) using FDG-PET, 12 had stable metabolic disease, and 2 had progressive metabolic disease after a 2-week treatment with everolimus alone. Five of 12 evaluable patients experienced a prostate-specific antigen (PSA) reduction ≥ 50% during treatment with everolimus together with docetaxel. All 4 patients with a PMR according to PET imaging experienced a PSA reduction in response to everolimus with docetaxel, and 3 of 4 had PSA declines ≥ 50%. Conclusion Everolimus 10 mg daily and docetaxel 60 mg/m2 was safe in CRPC patients and these were the recommended doses in combination. FDG-PET response might serve as a biomarker for target inhibition by mTOR inhibitors.

    KW - mTOR

    KW - PI3K

    KW - Positron emission tomography

    KW - Prostatic adenocarcinoma

    KW - PTEN

    UR - http://www.scopus.com/inward/record.url?scp=84924580967&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84924580967&partnerID=8YFLogxK

    U2 - 10.1016/j.clgc.2014.08.007

    DO - 10.1016/j.clgc.2014.08.007

    M3 - Article

    VL - 13

    SP - 113

    EP - 123

    JO - Clinical Genitourinary Cancer

    JF - Clinical Genitourinary Cancer

    SN - 1558-7673

    IS - 2

    ER -